Annual report pursuant to Section 13 and 15(d)

Organization and Basis of Presentation (Details Narrative)

v3.8.0.1
Organization and Basis of Presentation (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Nov. 25, 2014
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Number of common stock value issued                   $ 3,000 $ 9,013 $ 15,862
Losses from operations   $ 1,831 $ 2,110 $ 1,200 $ 3,121 $ 94,386 $ 1,894 $ 4,204 $ 5,334 8,262 105,819 $ 53,948
Cash and cash equivalents   $ 748       $ 3,605       $ 748 $ 3,605  
Cocrystal, Cocrystal Holdings, Inc [Member] | Series A Preferred Stock [Member]                        
Number of common stock value issued $ 184,800                      
Number of options to purchase of common stock $ 178,200                      
Number of options to purchase of common stock, shares 551,418                      
RFS Pharma, LLC [Member] | Series A Preferred Stock [Member]                        
Number of options to purchase of common stock $ 6,600